US FDA Hoping To Spur More ANDA Pre-Submission Meetings During GDUFA III

 
• By Derrick Gingery
  
Increase certainty
The FDA believes increasing pre-submission meetings for complex generic applications could boost first-cycle approvals. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics